SG11202000356VA - Macrocyclic compounds and uses thereof - Google Patents
Macrocyclic compounds and uses thereofInfo
- Publication number
- SG11202000356VA SG11202000356VA SG11202000356VA SG11202000356VA SG11202000356VA SG 11202000356V A SG11202000356V A SG 11202000356VA SG 11202000356V A SG11202000356V A SG 11202000356VA SG 11202000356V A SG11202000356V A SG 11202000356VA SG 11202000356V A SG11202000356V A SG 11202000356VA
- Authority
- SG
- Singapore
- Prior art keywords
- macrocyclic compounds
- macrocyclic
- compounds
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538193P | 2017-07-28 | 2017-07-28 | |
| US201862700990P | 2018-07-20 | 2018-07-20 | |
| PCT/US2018/043817 WO2019023417A1 (en) | 2017-07-28 | 2018-07-26 | Macrocyclic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000356VA true SG11202000356VA (en) | 2020-02-27 |
Family
ID=65039935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000356VA SG11202000356VA (en) | 2017-07-28 | 2018-07-26 | Macrocyclic compounds and uses thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11286264B2 (en) |
| EP (1) | EP3658148B1 (en) |
| JP (2) | JP7224334B2 (en) |
| KR (1) | KR102645316B1 (en) |
| CN (1) | CN111182903A (en) |
| AU (1) | AU2018306328B2 (en) |
| BR (1) | BR112020001695A2 (en) |
| CA (1) | CA3069232A1 (en) |
| CL (1) | CL2020000169A1 (en) |
| CO (1) | CO2020000633A2 (en) |
| DK (1) | DK3658148T3 (en) |
| FI (1) | FI3658148T3 (en) |
| IL (1) | IL271964B1 (en) |
| LT (1) | LT3658148T (en) |
| MY (1) | MY201925A (en) |
| PE (1) | PE20200700A1 (en) |
| PH (1) | PH12020500033A1 (en) |
| PL (1) | PL3658148T3 (en) |
| PT (1) | PT3658148T (en) |
| RS (1) | RS65884B1 (en) |
| SA (1) | SA520411108B1 (en) |
| SG (1) | SG11202000356VA (en) |
| TW (1) | TWI818917B (en) |
| UA (1) | UA126158C2 (en) |
| WO (1) | WO2019023417A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221518T1 (en) | 2014-01-24 | 2023-02-17 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| MX2017017097A (en) | 2015-07-02 | 2018-05-23 | Tp Therapeutics Inc | Chiral diaryl macrocycles as modulators of protein kinases. |
| RU2020123800A (en) | 2015-07-21 | 2020-10-02 | Тёрнинг Поинт Терапьютикс, Инк. | CHIRAL DIARYL MACROCYCLES AND THEIR APPLICATION |
| BR112019001607A2 (en) | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | macrocyclic kinase inhibitors |
| TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
| PT3658148T (en) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| CN109516999B (en) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | Compounds useful as protein kinase modulators and uses thereof |
| MX2020006490A (en) | 2017-12-19 | 2020-08-17 | Turning Point Therapeutics Inc | Macrocyclic compounds for treating disease. |
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| BR112021017996A2 (en) * | 2019-03-11 | 2021-11-16 | Esker Therapeutics Inc | Tyk2 inhibitors and their uses |
| CN113727984B (en) | 2019-05-21 | 2024-03-15 | 浙江海正药业股份有限公司 | Macrocyclic derivatives, preparation method and application thereof |
| WO2021063276A1 (en) * | 2019-09-30 | 2021-04-08 | 浙江海正药业股份有限公司 | Macrocyclic derivative, preparation method therefor and use thereof |
| EP4114530A4 (en) * | 2020-03-02 | 2024-04-17 | Turning Point Therapeutics, Inc. | Therapeutic uses of macrocyclic compounds |
| JP2023528907A (en) * | 2020-06-04 | 2023-07-06 | シンノハブ ファーマシューティカル カンパニー，リミティド | Compound having macrocyclic structure and use thereof |
| CN111620881B (en) * | 2020-07-08 | 2023-03-31 | 浙江合聚生物医药有限公司 | Raatinib derivative and preparation method and application thereof |
| WO2022171139A1 (en) * | 2021-02-10 | 2022-08-18 | 北京国鸿生物医药科技有限公司 | Macrocyclic compound, pharmaceutical composition, and use thereof |
| UY39779A (en) * | 2021-05-21 | 2023-01-31 | Blossomhill Therapeutics Inc | MACROCYCLIC COMPOUNDS TO TREAT DISEASES |
| CN116063326A (en) * | 2021-11-02 | 2023-05-05 | 赛诺哈勃药业（成都）有限公司 | Amino-containing macrocyclic compounds as protein kinase modulators |
| EP4433462A1 (en) * | 2021-11-16 | 2024-09-25 | Prodeg, LLC | Usp9x inhibitors |
| IL313670A (en) | 2021-12-30 | 2024-08-01 | Biomea Fusion Inc | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0690843B1 (en) | 1993-03-25 | 2000-08-30 | PHARMACIA & UPJOHN COMPANY | Formyl- or cyano- substituted indole derivatives having dopaminergic activity |
| PT657458E (en) | 1993-12-07 | 2002-02-28 | Lilly Co Eli | PROTEIN INHIBITORS CINASE C |
| RS49779B (en) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| ATE328888T1 (en) | 2000-08-25 | 2006-06-15 | Sloan Kettering Inst Cancer | RADICICOL AND MONOCILLIN AND THEIR ANALOGUES AND THEIR APPLICATIONS |
| MXPA03005139A (en) | 2000-12-08 | 2004-01-29 | Ortho Mcneil Pharm Inc | Macroheterocylic compounds useful as kinase inhibitors. |
| MX2011002470A (en) | 2008-09-08 | 2011-04-05 | Merck Patent Gmbh | Macrocyclics pyrimidines as aurora kinase inhibitors. |
| PL2350075T3 (en) | 2008-09-22 | 2014-07-31 | Array Biopharma Inc | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| BRPI0919873B8 (en) | 2008-10-22 | 2021-05-25 | Array Biopharma Inc | substituted pyrazol[1,5-a]pyrimidine compounds as trk kinase inhibitors, their preparation processes and pharmaceutical compositions |
| AU2009308675A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
| EP2488521B1 (en) | 2009-10-13 | 2013-12-18 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| SA111320200B1 (en) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors |
| LT3205654T (en) | 2010-05-20 | 2019-05-27 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| JP4868628B1 (en) | 2011-06-10 | 2012-02-01 | 株式会社メンテック | Antifouling composition |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EP2744331A4 (en) | 2011-08-19 | 2015-01-21 | Merck Sharp & Dohme | Methods and intermediates for preparing macrolactams |
| BR112014007622A2 (en) | 2011-09-30 | 2017-04-04 | Oncodesign Sa | macrocyclic flt3 kinase inhibitors |
| LT2822953T (en) | 2012-03-06 | 2017-04-10 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| NZ630721A (en) | 2012-03-09 | 2016-12-23 | Lexicon Pharmaceuticals Inc | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
| ES2676826T3 (en) | 2012-03-09 | 2018-07-25 | Lexicon Pharmaceuticals, Inc. | Compounds based on imidazo [1,2-b] pyridazine, compositions comprising them and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| HRP20221518T1 (en) * | 2014-01-24 | 2023-02-17 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| TWI688567B (en) * | 2014-09-11 | 2020-03-21 | 美商特普醫葯公司 | Diaryl macrocycles as modulators of protein kinases |
| MX2017017097A (en) | 2015-07-02 | 2018-05-23 | Tp Therapeutics Inc | Chiral diaryl macrocycles as modulators of protein kinases. |
| PT3319969T (en) | 2015-07-06 | 2024-06-17 | Turning Point Therapeutics Inc | Diaryl macrocycle polymorph |
| RU2020123800A (en) * | 2015-07-21 | 2020-10-02 | Тёрнинг Поинт Терапьютикс, Инк. | CHIRAL DIARYL MACROCYCLES AND THEIR APPLICATION |
| BR112019001607A2 (en) * | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | macrocyclic kinase inhibitors |
| TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
| PT3658148T (en) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| WO2019120267A1 (en) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | Imidazo[1,2-b]pyridazine macrocyclic kinase inhibitor |
| AU2019254979B2 (en) | 2018-04-18 | 2021-08-12 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-07-26 PT PT188382741T patent/PT3658148T/en unknown
- 2018-07-26 IL IL271964A patent/IL271964B1/en unknown
- 2018-07-26 RS RS20240945A patent/RS65884B1/en unknown
- 2018-07-26 BR BR112020001695-0A patent/BR112020001695A2/en unknown
- 2018-07-26 CN CN201880049611.1A patent/CN111182903A/en active Pending
- 2018-07-26 SG SG11202000356VA patent/SG11202000356VA/en unknown
- 2018-07-26 CA CA3069232A patent/CA3069232A1/en active Pending
- 2018-07-26 EP EP18838274.1A patent/EP3658148B1/en active Active
- 2018-07-26 PL PL18838274.1T patent/PL3658148T3/en unknown
- 2018-07-26 LT LTEPPCT/US2018/043817T patent/LT3658148T/en unknown
- 2018-07-26 AU AU2018306328A patent/AU2018306328B2/en active Active
- 2018-07-26 US US16/634,289 patent/US11286264B2/en active Active
- 2018-07-26 FI FIEP18838274.1T patent/FI3658148T3/en active
- 2018-07-26 DK DK18838274.1T patent/DK3658148T3/en active
- 2018-07-26 MY MYPI2019007871A patent/MY201925A/en unknown
- 2018-07-26 PE PE2020000127A patent/PE20200700A1/en unknown
- 2018-07-26 JP JP2020504026A patent/JP7224334B2/en active Active
- 2018-07-26 KR KR1020207000229A patent/KR102645316B1/en active IP Right Grant
- 2018-07-26 WO PCT/US2018/043817 patent/WO2019023417A1/en active Application Filing
- 2018-07-26 UA UAA202000271A patent/UA126158C2/en unknown
- 2018-07-27 TW TW107126181A patent/TWI818917B/en active
-
2020
- 2020-01-02 PH PH12020500033A patent/PH12020500033A1/en unknown
- 2020-01-20 CL CL2020000169A patent/CL2020000169A1/en unknown
- 2020-01-21 SA SA520411108A patent/SA520411108B1/en unknown
- 2020-01-21 CO CONC2020/0000633A patent/CO2020000633A2/en unknown
-
2021
- 2021-03-25 US US17/213,093 patent/US11155563B2/en active Active
-
2022
- 2022-02-22 US US17/676,942 patent/US11981684B2/en active Active
-
2023
- 2023-02-07 JP JP2023016586A patent/JP7554300B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271964A (en) | Macrocyclic compounds and uses thereof | |
| IL273236A (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| GB201714745D0 (en) | New compounds and uses | |
| IL288991A (en) | Macrocyclic compound and uses thereof | |
| GB201714740D0 (en) | New compounds and uses | |
| GB201714734D0 (en) | New compounds and uses | |
| IL292488B1 (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| GB201714736D0 (en) | New compounds and uses | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| IL292482B2 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201810121D0 (en) | Macrocyclic compounds and uses thereof | |
| GB201720092D0 (en) | New Compounds and uses | |
| GB201719327D0 (en) | New compounds and uses | |
| GB201719233D0 (en) | New compounds and uses | |
| GB201715210D0 (en) | Macrocyclic compounds | |
| GB201714743D0 (en) | New compounds and uses | |
| GB201704125D0 (en) | Macrocyclic Compounds | |
| GB201704121D0 (en) | Macrocyclic compounds |